Anticancer drugs are presently guarantying more survivors as a result of more powerful
drugs or combinations of drugs used in therapy. Thus, it has become more crucial to study …

Sunitinib (SUN) is an oral tyrosine kinase inhibitor approved in 2006 as a first-line treatment
for metastatic renal cell cancer. However, weak selectivity to kinase receptors and …

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15
years, are limited in their clinical application due to serious side effects. Therefore, we …

Transforming growth factor beta (TGF-β) promotes cancer growth in late stage cancers. To
inhibit the TGF-β pathway, we investigated a tumor-targeting TGF-β receptor blocker, TTB …

AKR1C3 overexpression has been reported in various types of cancers, including T-ALL.
AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent …

US11160870B2 - Extended release microparticles and suspensions thereof for medical therapy
- Google Patents US11160870B2 - Extended release microparticles and suspensions thereof …

Overexpression of AKR1C3, an aldo‐keto reductase, was recently discovered in liver
cancers. In this study, an inverse correlation between AKR1C3 expression and survival of …

Cancer cells are characterized by uncontrolled proliferation after escaping from inherent
physiological constraints on growth and survival and by destructive invasion of the healthy …

Background The toxicity of Sunitinib limits its clinical application. A new compound AST-003
was designed and synthesized based on the structure of Sunitinib, and previous study has …

2020-02-03 Assigned to Graybug Vision, Inc. reassignment Graybug Vision, Inc.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …